176 related articles for article (PubMed ID: 18628519)
1. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
[TBL] [Abstract][Full Text] [Related]
2. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
[TBL] [Abstract][Full Text] [Related]
4. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
Olié V; Plu-Bureau G; Conard J; Horellou MH; Canonico M; Scarabin PY
Menopause; 2011 May; 18(5):488-93. PubMed ID: 21178641
[TBL] [Abstract][Full Text] [Related]
5. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
[TBL] [Abstract][Full Text] [Related]
6. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
Scarabin PY; Oger E; Plu-Bureau G;
Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
[TBL] [Abstract][Full Text] [Related]
7. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
8. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
Canonico M; Oger E; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
J Thromb Haemost; 2006 Jun; 4(6):1259-65. PubMed ID: 16706969
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy and venous thromboembolism among postmenopausal women.
Scarabin PY
Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
[TBL] [Abstract][Full Text] [Related]
13. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
[TBL] [Abstract][Full Text] [Related]
14. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
Scarabin PY
Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359
[TBL] [Abstract][Full Text] [Related]
15. Hormones and venous thromboembolism among postmenopausal women.
Scarabin PY
Climacteric; 2014 Dec; 17 Suppl 2():34-7. PubMed ID: 25223916
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
Canonico M
Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
[TBL] [Abstract][Full Text] [Related]
17. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
Jick H; Derby LE; Myers MW; Vasilakis C; Newton KM
Lancet; 1996 Oct; 348(9033):981-3. PubMed ID: 8855853
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
[TBL] [Abstract][Full Text] [Related]
19. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
Renoux C; Dell'Aniello S; Brenner B; Suissa S
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
[TBL] [Abstract][Full Text] [Related]
20. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
